Related Experiment Videos
Glucocorticoid-regulated VEGF expression in ischemic skeletal muscle
Issam A Halaby1, Sean P Lyden, Mark G Davies
1Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|February 28, 2002
Summary
A novel gene therapy approach uses a regulated plasmid to control vascular endothelial growth factor (VEGF) expression, enabling safer therapeutic neovascularization for ischemic tissues.
Area of Science:
- Molecular Biology
- Gene Therapy
- Cardiovascular Research
Background:
- Vascular endothelial growth factor (VEGF) promotes new blood vessel growth.
- Gene therapy using VEGF shows promise for treating ischemic conditions.
- Uncontrolled VEGF expression can lead to adverse effects like hypervascularization.
Purpose of the Study:
- To develop a regulated gene transfer system for controlling VEGF expression.
- To create a safer and more precise therapeutic approach for neovascularization.
Main Methods:
- Developed a glucocorticoid-regulated plasmid vector (pNGVL-hAP/GRE(5)-vegf-pA) for VEGF gene expression.
- Delivered the plasmid via intramuscular injection to mice and rabbits with induced ischemia.
- Administered dexamethasone (DEX) to regulate VEGF expression.
Main Results:
- Dexamethasone (DEX) treatment significantly enhanced VEGF expression and collateral vessel development in ischemic rabbit muscle.
- VEGF transgene expression was reinduced upon reintroduction of DEX.
- The system demonstrated fine-tuned control over VEGF-driven neovascularization.
Conclusions:
- Glucocorticoid-regulated VEGF gene transfer offers a controlled method for therapeutic angiogenesis.
- This technology provides a safer alternative to constitutive VEGF gene delivery for ischemic diseases.
- The system allows for precise modulation of VEGF expression to promote neovascularization.